MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
1.640
+0.140
+9.33%
After Hours: 1.650 +0.01 +0.61% 19:57 02/06 EST
OPEN
1.510
PREV CLOSE
1.500
HIGH
1.675
LOW
1.510
VOLUME
2.92M
TURNOVER
--
52 WEEK HIGH
2.640
52 WEEK LOW
0.5300
MARKET CAP
244.37M
P/E (TTM)
-0.5510
1D
5D
1M
3M
1Y
5Y
1D
Palisade Bio präsentiert auf Oppenheimer Healthcare Life Sciences Conference
Reuters · 2d ago
Palisade Bio to Present at Oppenheimer Healthcare Life Sciences Conference
Reuters · 2d ago
Weekly Report: what happened at PALI last week (0126-0130)?
Weekly Report · 5d ago
Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board
TipRanks · 01/29 13:50
Palisade Bio Names IBD Experts to Clinical Advisory Board
Reuters · 01/29 13:45
PALISADE BIO APPOINTS LEADING GLOBAL IBD EXPERTS, LAURENT PEYRIN-BIROULET, MD, PHD AND DAVID T. RUBIN, MD, TO ITS CLINICAL ADVISORY BOARD
Reuters · 01/29 13:45
Weekly Report: what happened at PALI last week (0119-0123)?
Weekly Report · 01/26 09:10
Palisade Bio Director Donald Allen Williams Reports Acquisition of Common Shares
Reuters · 01/21 21:06
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.